The weight-loss drug market is expected to top £100B by 2030. Early leaders are surging. Novo Nordisk’s sales jumped 30% last year, while others race to keep up through R&D pivots, licensing, and acquisitions.
But the real-world impact goes beyond clinical data.
Our latest UK report reveals behavioural signals from 11K adults and 3.8K tracked shoppers:
- Calorie intake drops among active GLP-1 users
- Spend shifts across food, alcohol, OTC and wellness categories
- New openings for partnerships, messaging, and evidence generation
If you’re planning strategy, positioning or go-to-market for an obesity or weight-management treatment, this data matters.
Client Title